Top Markets
#1 CoW Protocol CoW Protocol +84.93%
#2 EXOD EXOD +56.80%
#3 Glidr Glidr +38.25%
#4 Walrus Walrus +36.32%
#5 Humanity Humanity +16.84%
#6 Velvet Velvet +16.00%
#7 Cysic Cysic +15.83%
#8 The Black Bull The Black Bull +14.62%
#9 Tutorial Tutorial +14.59%
#10 Plume Plume +14.14%
Coin of the day
CoW Protocol CoW Protocol
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Kedudukan dalam Saham #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Harga Saham
$0.07600875
Disegerakkan terakhir: 2024-11-20
Modal Pasaran
$2.06M
Perubahan (1 hari)
-0.51%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Quantum Genomics S.A. (ALQGC)

Kategori

Healthcare
Hasil untuk Quantum Genomics S.A. (ALQGC)
Hasil pada Dec 2024 TTM: $2.14K
Menurut laporan kewangan terkini daripada Quantum Genomics S.A., hasil semasa syarikat (TTM) ialah $2.14K. Pada tahun 2023, syarikat memperoleh hasil sebanyak $21.88K penurunan berbanding hasil pada tahun 2022 iaitu $2.70M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Quantum Genomics S.A. dari 2009 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $2.14K 20,481.43%
2024 $10.41 -99.95%
2023 $21.88K -99.19%
2022 $2.70M -24.40%
2021 $3.57M 60.20%
2020 $2.23M 28.33%
2019 $1.74M 40,877.53%
2018 $4.24K 0.00%
2017 0.00 0.00%
2016 0.00 -100.00%
2015 $156.51K -60.11%
2014 $392.39K 1,539.89%
2013 $23.93K -5.52%
2012 $25.33K 1.90%
2011 $24.85K -3.18%
2010 $25.67K -6.76%
2009 $27.53K 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 589,224,844.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 281,036,684.84%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 471,909,450.14%
BE